Skip to content
10-Q

Quarterly Report

Goldenwell Biotech, Inc. GWLL

0001477932-25-004186

← back to feed
Filed
May 27, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 21, 2025 99M sh
Shares Diluted Q1 2025 · Mar 31, 2025 99M sh
Shares Diluted Q1 2025 · Mar 31, 2024 99M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$32.28K
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$29.01K
Long Term Debt Q1 2025 · Mar 31, 2025 $176.09K
Long Term Debt Q1 2025 · Dec 31, 2024 $173.99K
Stockholders Equity Q1 2025 · Mar 31, 2025 −$81.62K
Stockholders Equity Q1 2025 · Dec 31, 2024 −$47.24K
Stockholders Equity restated Q1 2025 · Mar 31, 2024 $53.2K
Stockholders Equity restated Q1 2025 · Dec 31, 2023 $84.26K
Total Liabilities Q1 2025 · Mar 31, 2025 $273.53K
Total Liabilities Q1 2025 · Dec 31, 2024 $271.43K
Total Assets Q1 2025 · Mar 31, 2025 $191.92K
Total Assets Q1 2025 · Dec 31, 2024 $224.19K
Eps Diluted Q1 2025 · Mar 31, 2025 $0.00
Eps Diluted Q1 2025 · Mar 31, 2024 $0.00
Net Income Q1 2025 · Mar 31, 2025 −$34.38K
Net Income restated Q1 2025 · Mar 31, 2024 −$31.06K
Operating Income Q1 2025 · Mar 31, 2025 −$32.28K
Operating Income restated Q1 2025 · Mar 31, 2024 −$28.96K
Gross Profit Q1 2025 · Mar 31, 2025 $0
Gross Profit restated Q1 2025 · Mar 31, 2024 $0
Cost Of Revenue Q1 2025 · Mar 31, 2025 $0
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $0